CTLA4 and neoplasm: Humanised monoclonal antibody ICIs, including PD-1, CTLA-4, LAG-3 and TIM-3, target T cell immunoregulatory receptors utilised by tumours to suppress the immune response, promoting T cell mediated tumour recognition, cytotoxicity and death [75].